Cancer Cell Biology

You have full text access to this OnlineOpen article

Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model

  1. Marco A. Carvalho1,
  2. Karina G. Zecchin2,
  3. Fabiana Seguin1,
  4. Débora C. Bastos1,
  5. Michelle Agostini1,
  6. Ana Lúcia C.A. Rangel1,
  7. Sílvio S. Veiga3,
  8. Helena F. Raposo4,
  9. Helena C.F. Oliveira4,
  10. Massimo Loda5,
  11. Ricardo D. Coletta1,
  12. Edgard Graner1,†,*

Article first published online: 3 SEP 2008

DOI: 10.1002/ijc.23835

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 11, pages 2557–2565, 1 December 2008

Additional Information

How to Cite

Carvalho, M. A., Zecchin, K. G., Seguin, F., Bastos, D. C., Agostini, M., Rangel, A. L. C.A., Veiga, S. S., Raposo, H. F., Oliveira, H. C.F., Loda, M., Coletta, R. D. and Graner, E. (2008), Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int. J. Cancer, 123: 2557–2565. doi: 10.1002/ijc.23835

Author Information

  1. 1

    Department of Oral Diagnosis, School of Dentistry of Piracicaba, State University of Campinas (UNICAMP), Piracicaba, Sao Paulo, Brazil

  2. 2

    Department of Clinical Pathology, School of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil

  3. 3

    Department of Cell Biology, Federal University of Paraná, Brazil

  4. 4

    Department of Physiology and Biophysics, Institute of Biology, State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil

  5. 5

    Medical Oncology, Dana-Farber Cancer Institute and Pathology Department, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

  1. †

    Fax: 55-19-2106-5318.

*Department of Oral Diagnosis, School of Dentistry of Piracicaba, State University of Campinas (UNICAMP), Avenida Limeira 901, CP 52, Areão, Piracicaba, Sao Paulo, 13414-018, Brazil

Publication History

  1. Issue published online: 24 SEP 2008
  2. Article first published online: 3 SEP 2008
  3. Manuscript Accepted: 20 JUN 2008
  4. Manuscript Received: 9 NOV 2007

Funded by

  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Grant Numbers: 04/13903-0, 02/08030-1
  • FAPESP fellowships. Grant Numbers: 05/52631-8, 05/50297-3, 04/13904-6, 04/06397-0
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico fellowships. Grant Numbers: PIBIC-CNPq, 151125/2005-8

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (635K)

References

  • 1
    Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000; 16: 202–8.
  • 2
    Weiss L,Hoffmann GE,Schreiber R,Andres H,Fuchs E,Korber E,Kolb HJ. Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe Seyler 1986; 367: 905–12.
  • 3
    Pizer ES,Wood FD,Heine HS,Romantsev FE,Pasternack GR,Kuhajda FP. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996; 56: 1189–93.
  • 4
    Gansler TS,Hardman W,III,Hunt DA,Schaffel S,Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997; 28: 686–92.
  • 5
    Alo PL,Visca P,Marci A,Mangoni A,Botti C,Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996; 77: 474–82.
    Direct Link:
  • 6
    Krontiras H,Roye GD,Beenken SE,Myers RB,Mayo MS,Peters GE,Grizzle WE. Fatty acid synthase expression is increased in neoplastic lesions of the oral tongue. Head Neck 1999; 21: 325–9.
    Direct Link:
  • 7
    Piyathilake CJ,Frost AR,Manne U,Bell WC,Weiss H,Heimburger DC,Grizzle WE. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000; 31: 1068–73.
  • 8
    Dhanasekaran SM,Barrette TR,Ghosh D,Shah R,Varambally S,Kurachi K,Pienta KJ,Rubin MA,Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822–6.
  • 9
    Shurbaji MS,Kalbfleisch JH,Thurmond TS. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 1996; 27: 917–21.
  • 10
    Kusakabe T,Nashimoto A,Honma K,Suzuki T. Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 2002; 40: 71–9.
    Direct Link:
  • 11
    Swinnen JV,Roskams T,Joniau S,Van Poppel H,Oyen R,Baert L,Heyns W,Verhoeven G. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002; 98: 19–22.
    Direct Link:
  • 12
    Innocenzi D,Alo PL,Balzani A,Sebastiani V,Silipo V,La Torre G,Ricciardi G,Bosman C,Calvieri S. Fatty acid synthase expression in melanoma. J Cutan Pathol 2003; 30: 23–8.
    Direct Link:
  • 13
    Rossi S,Graner E,Febbo P,Weinstein L,Bhattacharya N,Onody T,Bubley G,Balk S,Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 2003; 1: 707–15.
  • 14
    Visca P,Sebastiani V,Pizer ES,Botti C,De Carli P,Filippi S,Monaco S,Alo PL. Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. Anticancer Res 2003; 23: 335–9.
  • 15
    Takahiro T,Shinichi K,Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 2003; 9: 2204–12.
  • 16
    Rossi S,Ou W,Tang D,Bhattacharya N,Dei Tos AP,Fletcher JA,Loda M. Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol 2006; 209: 369–75.
    Direct Link:
  • 17
    Furuya Y,Akimoto S,Yasuda K,Ito H. Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis. Anticancer Res 1997; 17: 4589–93.
  • 18
    Pizer ES,Chrest FJ,DiGiuseppe JA,Han WF. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 1998; 58: 4611–15.
  • 19
    Li JN,Gorospe M,Chrest FJ,Kumaravel TS,Evans MK,Han WF,Pizer ES. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 2001; 61: 1493–9.
  • 20
    Zhou W,Simpson PJ,McFadden JM,Townsend CA,Medghalchi SM,Vadlamudi A,Pinn ML,Ronnett GV,Kuhajda FP. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 2003; 63: 7330–7.
  • 21
    Pizer ES,Pflug BR,Bova GS,Han WF,Udan MS,Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 2001; 47: 102–10.
    Direct Link:
  • 22
    Pizer ES,Thupari J,Han WF,Pinn ML,Chrest FJ,Frehywot GL,Townsend CA,Kuhajda FP. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000; 60: 213–18.
  • 23
    Alli PM,Pinn ML,Jaffee EM,McFadden JM,Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 2005; 24: 39–46.
  • 24
    Kridel SJ,Axelrod F,Rozenkrantz N,Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004; 64: 2070–5.
  • 25
    Menendez JA,Vellon L,Lupu R. Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med (Maywood) 2005; 230: 151–4.
  • 26
    Menendez JA,Vellon L,Lupu R. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 2005; 16: 1253–67.
  • 27
    Knowles LM,Axelrod F,Browne CD,Smith JW. A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 2004; 279: 30540–5.
  • 28
    Lacasa D,Le Liepvre X,Ferre P,Dugail I. Progesterone stimulates adipocyte determination and differentiation 1/sterol regulatory element-binding protein 1c gene expression. potential mechanism for the lipogenic effect of progesterone in adipose tissue. J Biol Chem 2001; 276: 11512–16.
  • 29
    Swinnen JV,Esquenet M,Goossens K,Heyns W,Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 1997; 57: 1086–90.
  • 30
    Swinnen JV,Heemers H,Deboel L,Foufelle F,Heyns W,Verhoeven G. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 2000; 19: 5173–81.
  • 31
    Heemers H,Maes B,Foufelle F,Heyns W,Verhoeven G,Swinnen JV. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 2001; 15: 1817–28.
  • 32
    Van de Sande T,De Schrijver E,Heyns W,Verhoeven G,Swinnen JV. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 2002; 62: 642–6.
  • 33
    Graner E,Tang D,Rossi S,Baron A,Migita T,Weinstein LJ,Lechpammer M,Huesken D,Zimmermann J,Signoretti S,Loda M. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 2004; 5: 253–61.
  • 34
    Ries LAG,Eisner MP,Kosary CL,Hankey BF,Miller BA,Clegg L,Mariotto A,Fay MP,Feuer EJ,Edwards BK. SEER Cancer statistics review, 1975–2000. Bethesda, MD: National Cancer Institute, 2003.
  • 35
    Kapur P,Rakheja D,Roy LC,Hoang MP. Fatty acid synthase expression in cutaneous melanocytic neoplasms. Mod Pathol 2005; 18: 1107–12.
  • 36
    Bennett DC,Cooper PJ,Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987; 39: 414–18.
    Direct Link:
  • 37
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54.
  • 38
    Ando H,Funasaka Y,Oka M,Ohashi A,Furumura M,Matsunaga J,Matsunaga N,Hearing VJ,Ichihashi M. Possible involvement of proteolytic degradation of tyrosinase in the regulatory effect of fatty acids on melanogenesis. J Lipid Res 1999; 40: 1312–16.
  • 39
    Khanna C,Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005; 26: 513–23.
  • 40
    Dietschy JM,Spady DK. Measurement of rates of cholesterol synthesis using tritiated water. J Lipid Res 1984; 25: 1469–76.
  • 41
    Osono Y,Woollett LA,Herz J,Dietschy JM. Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J Clin Invest 1995; 95: 1124–32.
  • 42
    Oliveira HC,Cosso RG,Alberici LC,Maciel EN,Salerno AG,Dorighello GG,Velho JA,de Faria EC,Vercesi AE. Oxidative stress in atherosclerosis-prone mouse is due to low antioxidant capacity of mitochondria. FASEB J 2005; 19: 278–80.
  • 43
    Levin MS,Talkad VD,Gordon JI,Stenson WF. Trafficking of exogenous fatty acids within Caco-2 cells. J Lipid Res 1992; 33: 9–19.
  • 44
    Swinnen JV,Van Veldhoven PP,Esquenet M,Heyns W,Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 1996; 137: 4468–74.
  • 45
    Ando H,Watabe H,Valencia JC,Yasumoto K,Furumura M,Funasaka Y,Oka M,Ichihashi M,Hearing VJ. Fatty acids regulate pigmentation via proteasomal degradation of tyrosinase: a new aspect of ubiquitin-proteasome function. J Biol Chem 2004; 279: 15427–33.
  • 46
    McNeely W,Benfield P. Orlistat. Drugs 1998; 56: 241–9; discussion 50.
  • 47
    Ho TS,Ho YP,Wong WY,Chi-Ming Chiu L,Wong YS,Eng-Choon Ooi V. Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. Biomed Pharmacother 2007; 61: 578–87.
  • 48
    Chirala SS,Chang H,Matzuk M,Abu-Elheiga L,Mao J,Mahon K,Finegold M,Wakil SJ. Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci USA 2003; 100: 6358–63.
  • 49
    Rossi S,Ou W,Tang D,Bhattacharya N,Dei Tos AP,Fletcher JA,Loda M. Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol 2006; 209: 369–75.
    Direct Link:
  • 50
    Ramaswamy S,Ross KN,Lander ES,Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49–54.
  • 51
    Swinnen JV,Van Veldhoven PP,Timmermans L,De Schrijver E,Brusselmans K,Vanderhoydonc F,Van de Sande T,Heemers H,Heyns W,Verhoeven G. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003; 302: 898–903.
  • 52
    Poste G,Doll J,Hart IR,Fidler IJ. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 1980; 40: 1636–44.
  • 53
    Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973; 242: 148–9.
  • 54
    Chan WS,Page CM,Maclellan JR,Turner GA. The growth and metastasis of four commonly used tumour lines implanted into eight different sites: evidence for site and tumour effects. Clin Exp Metastasis 1988; 6: 233–44.
  • 55
    Kawada K,Sonoshita M,Sakashita H,Takabayashi A,Yamaoka Y,Manabe T,Inaba K,Minato N,Oshima M,Taketo MM. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004; 64: 4010–17.
  • 56
    Ito D,Back TC,Shakhov AN,Wiltrout RH,Nedospasov SA. Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment. J Immunol 1999; 163: 2809–15.
  • 57
    Vantyghem SA,Postenka CO,Chambers AF. Estrous cycle influences organ-specific metastasis of B16F10 melanoma cells. Cancer Res 2003; 63: 4763–5.
  • 58
    Browne CD,Hindmarsh EJ,Smith JW. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 2006; 20: 2027–35.
View Full Article (HTML) Get PDF (635K)